Drug Trial Radar · NCT01255761
A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects
Last checked: Nov 20, 2026Latest source record: Jul 31, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
736
Actual
Start
Nov 2010
Primary completion
Oct 2012
Study completion Dec 2012
Sponsor
- Lead sponsor
- UCB PharmaUCB
- Sponsor type
- Industry
- First posted
- Dec 7, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 4 study to evaluate a routine patient completed assessment (RAPID3) compared to a physician completed assessment (CDAI) to predict treatment success with subjects with moderate to severe rheumatoid arthritis
Conditions
- Rheumatoid Arthritis
Interventions
Certolizumab Pegol (CZP)Biological
400 mg subcutaneous injection at Weeks 0, 2 and 4 200 mg subcutaneous injection every two weeks, Week 6 through Week 52
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response at Week 12 as Assessed by Randomized Tool [Clinical Disease Activity Index (CDAI) or Routine Assessment of Patient Index Data 3 (RAPID3)]Time frame: Baseline (Week 0) to Week 12
- Responders at Week 12 (as Assessed by Randomized Tool Clinical Disease Activity Index [CDAI] or Routine Assessment of Patient Index Data [RAPID3]) Achieving Low Disease Activity (Disease Activity Score 28 [Erythrocyte Sedimentation Rate]≤3.2) at Week 52Time frame: Baseline (Week 0) to Week 52
Locations
110 sites in 1 country. Site status is shown where the registry gives one.
137
Birmingham, Alabama
166
Huntsville, Alabama
165
Peoria, Arizona
216
Tucson, Arizona
168
Hot Springs, Arkansas
241
Jonesboro, Arkansas
153
Little Rock, Arkansas
111
Covina, California
208
Escondido, California
103
Fullerton, California
155
Huntington Beach, California
202
La Mesa, California
203
Loma Linda, California
233
Los Angeles, California
105
Palm Desert, California
229
Roseville, California
113
Sacramento, California
127
San Diego, California
106
Santa Maria, California
172
Santa Monica, California
212
Upland, California
231
Van Nuys, California
158
Whittier, California
121
Bridgeport, Connecticut
200
Bridgeport, Connecticut
107
Danbury, Connecticut
195
Danbury, Connecticut
138
Hamden, Connecticut
218
Lewes, Delaware
108
Aventura, Florida
120
Dunedin, Florida
101
Ocala, Florida
225
Orange Park, Florida
227
Ormond Beach, Florida
184
Palm Harbor, Florida
145
Sarasota, Florida
191
Tampa, Florida
236
Vero Beach, Florida
144
Atlanta, Georgia
232
Atlanta, Georgia
Showing 40 of 110 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.